Validation of the Itch Reported Outcome (ItchRO) Diaries in Pediatric Cholestatic Liver Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

23 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-07-31

Study Completion Date

2015-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to validate the ItchRO instrument (a clinical outcome assessment measure of itching) prior to the analysis of longitudinal treatment effect data being generated in ongoing clinical trials.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome

NCT02057692

Alagille Syndrome

COMPLETED PHASE2

Safety and Efficacy Study of LUM001 in the Treatment of Cholestatic Liver Disease in Patients With Alagille Syndrome

NCT01903460

Alagille Syndrome

COMPLETED PHASE2

A4250, an IBAT Inhibitor in Pediatric Cholestasis

NCT02630875

Pediatric Cholestasis

COMPLETED PHASE2

Phase I Trial of Silymarin for Chronic Liver Diseases

NCT00389376

Hepatitis C Non-Alcoholic Fatty Liver Disease

COMPLETED PHASE1

Phase I Study of Colchicine Therapy in Childhood Hepatic Cirrhosis

NCT00004368

Cirrhosis Liver Cirrhosis

UNKNOWN PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This research will examine the psychometric performance of the electronic diaries for the itch-reported outcome (ItchRO) measure for both patients and caregivers in a stand-alone 2-week validation study in the target patient population. The study is non-interventional in nature; the purpose of the study is to validate the ItchRO prior to the analysis of longitudinal treatment effect data being generated in ongoing clinical trials. Following training and initial completion of the electronic diaries, families will return home and complete the diaries twice daily over the course of two weeks. Additional assessments include the numerical rating scale to assess itching, the patient impression of change (PIC), the caregiver impression of change (CIC), PedsQL (pediatric quality of life), children's sleep habits questionnaire (CSHQ), and clinical scratch scale.

Longitudinal data will be used to follow the natural (non-interventional) course of the disease and the quality of the data. Test-retest reliability will be assessed using diary data from Day 1 to Day 14 in stable subjects as measured by the PIC for the child-completed measure and the CIC for the caregiver measure. Convergent validity (correlations between the ItchRO and similar concepts on the other measures included in the study) will also be explored (such as the correlation between sleep and morning ItchRO diary scores). Clinical validity (correlation between the ItchRO and clinician reports) and preliminary responsiveness of those who changed in their itching status over the two week period will also be assessed if sample sizes allow.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alagille Syndrome Progressive Familial Intrahepatic Cholestasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Validation Group

Subjects with ALGS or PFIC and/or their caregivers

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. The subject has voluntarily provided verbal assent or written assent in accordance with the site's Institutional Review Board (IRB) guidelines;
2. The subject's legal guardian has voluntarily provided permission for study participation and authorization for access to personal health information in conjunction with HIPPA;
3. The subject has a diagnosis of ALGS or PFIC;
4. The subject is able to speak and comprehend US English (applicable only for children age 5 and older);
5. The subject is willing and able to participate in the two-week validation study (applicable only for children age 5 and older); and
6. The subject is able to understand the nature, scope, and possible consequences of the study, and/or does not present evidence of an uncooperative attitude (applicable only for children age 5 and older).

1. The caregiver voluntarily provided written informed consent;
2. The caregiver is 18 years of age or older;
3. The caregiver has served as a consistent caregiver for the subject with ALGS or PFIC;
5. The caregiver is able to speak, read, write, and comprehend US English;
6. The caregiver is willing and able to participate in the two-week validation study; and
7. The caregiver is able to understand the nature, scope, and possible consequences of the study, and/or does not present evidence of an uncooperative attitude.

Minimum Eligible Age

5 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No